Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance

Journal of Diabetes Investigation

Volumn 2, Issue 6, 2011, Pages 435-440

  Masuda, Kiyomi ^a   Aoki, Kazutaka ^b   Terauchi, Yasuo ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

Author keywords

Glucosidase inhibitor; Miglitol; Postprandial hyperglycemia

Indexed keywords

ALPHA GLUCOSIDASE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN; MIGLITOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; MALE; MORNING DOSAGE; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PRIORITY JOURNAL;

EID: 84857254870     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/j.2040-1124.2011.00129.x     Document Type: Article

References (21)

1. Macfarlane DP, Paterson KR, Fisher M. Oral anti diabetic agents as cardiovascular drugs. Diabetes Obes Metab 2007; 9: 23-30.
2. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006; 166: 1836-1841.
3. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005; 27: 1064-1073.
4. Masuda K, Aoki K, Kikuchi K, et al. Self-injection of insulin using appropriate supportive devices in handicapped subjects with diabetes. Diabetes Technol Ther 2010; 12: 483-490.
5. Nathan DM, Buse JB, Davidson MB. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963-1972.
6. Aoki K, Kato H, Terauchi Y. Divided-dose administration of miglitol just before and 15minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 2007; 54: 1009-1014.
7. Aoki K, Nakamura A, Ito S, et al. Administration of miglitol until 30min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract 2007; 78: 30-33.
8. Aoki K, Nakajima S, Nezu U, et al. Comparison of pre- vs. postmeal administration of miglitol for 3months in type 2 diabetic patients. Diabetes Obes Metab 2008; 10: 970-972.
9. Aoki K, Muraoka T, Ito Y, et al. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med 2010; 49: 1085-1087.
10. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009; 26: 187-188.
11. Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008; 57: 1299-1306.
12. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002; 4: 329-335.
13. Aoki K, Miyazaki T, Nagakura J, et al. Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucose dependent insulinotropic polypeptide levels in healthy men. Endocr J 2010; 57: 673-677.
14. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010; 1: 212-228.
15. Terauchi Y, Takamoto I, Kubota N, et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. J Clin Invest 2007; 117: 246-257.
16. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984; 26: 44-49.
17. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158.
18. Uttenthal LO, Ukponmwan OO, Wood SM, et al. Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas. Diabet Med 1986; 3: 155-160.
19. Seifarth C, Bergmann J, Holst JJ, et al. Prolonged and enhanced secretion of glucagon-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in Type 2 diabetic patients. Diabet Med 1998; 15: 485-491.
20. Hücking K, Kostic Z, Pox C, et al. Alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients. Diabet Med 2005; 22: 470-476.
21. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: similarities and differences. J Diabetes Invest 2010; 1: 8-23.